267 related articles for article (PubMed ID: 35777449)
21. Alcoholic and non-alcoholic fatty liver disease: Focus on ceramide.
Nikolova-Karakashian M
Adv Biol Regul; 2018 Dec; 70():40-50. PubMed ID: 30455063
[TBL] [Abstract][Full Text] [Related]
22. Metabolic Injury of Hepatocytes Promotes Progression of NAFLD and AALD.
Carvalho-Gontijo R; Han C; Zhang L; Zhang V; Hosseini M; Mekeel K; Schnabl B; Loomba R; Karin M; Brenner DA; Kisseleva T
Semin Liver Dis; 2022 Aug; 42(3):233-249. PubMed ID: 36001995
[TBL] [Abstract][Full Text] [Related]
23. The Presence of Periodontitis Exacerbates Non-Alcoholic Fatty Liver Disease via Sphingolipid Metabolism-Associated Insulin Resistance and Hepatic Inflammation in Mice with Metabolic Syndrome.
Lu Z; Li Y; Chowdhury N; Yu H; Syn WK; Lopes-Virella M; Yilmaz Ö; Huang Y
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176029
[TBL] [Abstract][Full Text] [Related]
24. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
Cusi K
Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
[TBL] [Abstract][Full Text] [Related]
25. Danhe granule ameliorates nonalcoholic steatohepatitis and fibrosis in rats by inhibiting ceramide de novo synthesis related to CerS6 and CerK.
Zhu M; Jia Z; Yan X; Liu L; Fang C; Feng M; Dai Y; Zhang Y; Wu H; Huang B; Li Y; Liu J; Xiao H
J Ethnopharmacol; 2022 Sep; 295():115427. PubMed ID: 35654350
[TBL] [Abstract][Full Text] [Related]
26. Role of ceramide-to-dihydroceramide ratios for insulin resistance and non-alcoholic fatty liver disease in humans.
Apostolopoulou M; Gordillo R; Gancheva S; Strassburger K; Herder C; Esposito I; Schlensak M; Scherer PE; Roden M
BMJ Open Diabetes Res Care; 2020 Nov; 8(2):. PubMed ID: 33219119
[TBL] [Abstract][Full Text] [Related]
27. Dihydrosphingolipids are associated with steatosis and increased fibrosis damage in non-alcoholic fatty liver disease.
Babiy B; Ramos-Molina B; Ocaña L; Sacristán S; Burgos-Santamaría D; Martínez-Botas J; Busto R; Perna C; Frutos MD; Albillos A; Pastor Ó
Biochim Biophys Acta Mol Cell Biol Lipids; 2023 Jul; 1868(7):159318. PubMed ID: 37059386
[TBL] [Abstract][Full Text] [Related]
28. Increased serum concentration of ceramides in obese children with nonalcoholic fatty liver disease.
Wasilewska N; Bobrus-Chociej A; Harasim-Symbor E; Tarasów E; Wojtkowska M; Chabowski A; Lebensztejn DM
Lipids Health Dis; 2018 Sep; 17(1):216. PubMed ID: 30208901
[TBL] [Abstract][Full Text] [Related]
29. Hepatocyte nuclear factor 4α in the pathogenesis of non-alcoholic fatty liver disease.
Pan X; Zhang Y
Chin Med J (Engl); 2022 May; 135(10):1172-1181. PubMed ID: 35191422
[TBL] [Abstract][Full Text] [Related]
30. Apoptosis and non-alcoholic fatty liver diseases.
Kanda T; Matsuoka S; Yamazaki M; Shibata T; Nirei K; Takahashi H; Kaneko T; Fujisawa M; Higuchi T; Nakamura H; Matsumoto N; Yamagami H; Ogawa M; Imazu H; Kuroda K; Moriyama M
World J Gastroenterol; 2018 Jul; 24(25):2661-2672. PubMed ID: 29991872
[TBL] [Abstract][Full Text] [Related]
31. Effects of constant light exposure on sphingolipidomics and progression of NASH in high-fat-fed rats.
Yue F; Xia K; Wei L; Xing L; Wu S; Shi Y; Lam SM; Shui G; Xiang X; Russell R; Zhang D
J Gastroenterol Hepatol; 2020 Nov; 35(11):1978-1989. PubMed ID: 32027419
[TBL] [Abstract][Full Text] [Related]
32. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Dhamija E; Paul SB; Kedia S
Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
[TBL] [Abstract][Full Text] [Related]
33. Acid sphingomyelinase-ceramide system in steatohepatitis: a novel target regulating multiple pathways.
Garcia-Ruiz C; Mato JM; Vance D; Kaplowitz N; Fernández-Checa JC
J Hepatol; 2015 Jan; 62(1):219-33. PubMed ID: 25281863
[TBL] [Abstract][Full Text] [Related]
34. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?
Firneisz G
World J Gastroenterol; 2014 Jul; 20(27):9072-89. PubMed ID: 25083080
[TBL] [Abstract][Full Text] [Related]
35. Exogenous Liposomal Ceramide-C6 Ameliorates Lipidomic Profile, Energy Homeostasis, and Anti-Oxidant Systems in NASH.
Zanieri F; Levi A; Montefusco D; Longato L; De Chiara F; Frenguelli L; Omenetti S; Andreola F; Luong TV; Massey V; Caballeria J; Fondevila C; Shanmugavelandy SS; Fox T; Mazza G; Argemi J; Bataller R; Cowart LA; Kester M; Pinzani M; Rombouts K
Cells; 2020 May; 9(5):. PubMed ID: 32429478
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic reversal of chronic alcohol-related steatohepatitis with the ceramide inhibitor myriocin.
Tong M; Longato L; Ramirez T; Zabala V; Wands JR; de la Monte SM
Int J Exp Pathol; 2014 Feb; 95(1):49-63. PubMed ID: 24456332
[TBL] [Abstract][Full Text] [Related]
37. Deranged hepatocyte intracellular Ca
Ali ES; Rychkov GY; Barritt GJ
Cell Calcium; 2019 Sep; 82():102057. PubMed ID: 31401389
[TBL] [Abstract][Full Text] [Related]
38. Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention.
Tacke F; Weiskirchen R
Ann Transl Med; 2021 Apr; 9(8):729. PubMed ID: 33987427
[TBL] [Abstract][Full Text] [Related]
39. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease.
Brown E; Hydes T; Hamid A; Cuthbertson DJ
Clin Ther; 2021 Sep; 43(9):1476-1504. PubMed ID: 34446271
[TBL] [Abstract][Full Text] [Related]
40. Intracellular and extracellular miRNome deregulation in cellular models of NAFLD or NASH: Clinical implications.
Di Mauro S; Ragusa M; Urbano F; Filippello A; Di Pino A; Scamporrino A; Pulvirenti A; Ferro A; Rabuazzo AM; Purrello M; Purrello F; Piro S
Nutr Metab Cardiovasc Dis; 2016 Dec; 26(12):1129-1139. PubMed ID: 27756518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
